Kiniksa Pharmaceuticals International, plc (KNSA) stock: key figures, P/E, revenue and dividend

Health Care · ISIN USG526941095

Price
79.48 USD
Market cap
6.28 bn USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Kiniksa Pharmaceuticals International, plc financials

Fiscal year2025
Revenue677.56 m USD
Gross profit599.89 m USD
Operating income77.22 m USD
EBIT77.23 m USD
Net income59.01 m USD
Diluted EPS – continuing operations0.75 USD

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 19.10.2026. Details in the risk notice.

Kiniksa Pharmaceuticals International, plc stock (KNSA): P/E, revenue, dividend | finmetric